πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 11 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12109198

Macrocyclic azolopyridine derivatives as EED and PRC2 modulators

Fulcrum Therapeutics, Inc. Β· Granted Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11819554

Compositions and methods for modulating FMR1 expression

Fulcrum Therapeutics, Inc. Β· Granted Tue Nov 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11590111

Macrocyclic azolopyridine derivatives as EED and PRC2 modulators

Fulcrum Therapeutics, Inc. Β· Granted Tue Feb 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11479770

Use of p38 inhibitors to reduce expression of DUX4

Fulcrum Therapeutics, Inc. Β· Granted Tue Oct 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11291659

P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD

Fulcrum Therapeutics, Inc. Β· Granted Tue Apr 05 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 31 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10973805

Macrocyclic azolopyridine derivatives as EED and PRC2 modulators

Fulcrum Therapeutics, Inc. Β· Granted Tue Apr 13 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10537560

P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD

Fulcrum Therapeutics, Inc. Β· Granted Tue Jan 21 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10342786

P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD

Fulcrum Therapeutics, Inc. Β· Granted Tue Jul 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9051379

Sp1 polypeptides, modified Sp1 polypeptides and uses thereof

Fulcrum SP Ltd. Β· Granted Tue Jun 09 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 04 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7253341

Denaturant stable and/or protease resistant, chaperone-like oligomeric proteins, polynucle

Fulcrum SP Ltd. Β· Granted Tue Aug 07 2007 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 02 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7183267

Ξ²-lactamase inhibitors and methods of use thereof

Fulcrum Pharmaceuticals Inc. Β· Granted Tue Feb 27 2007 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 22 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

granted